OncoMatch/Clinical Trials/NCT06746688
A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.
Is NCT06746688 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies ES2B-C001 for breast cancer.
Treatment: ES2B-C001 — The trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without \[adjuvant\], in patients with human epidermal growth factor receptor 2 (HER2) expressing metastatic breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) expression (ihc 1+, 2+ (fish negative or positive), or 3+)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anticancer therapy
after undergoing 2-3 lines of anticancer therapy
Lab requirements
Blood counts
adequate bone marrow function without clinically significant laboratory parameters as judged by the investigator
Kidney function
adequate kidney function without clinically significant laboratory parameters as judged by the investigator
Liver function
adequate liver function without clinically significant laboratory parameters as judged by the investigator
Cardiac function
adequate heart function without clinically significant laboratory parameters as judged by the investigator; 12-lead ECG without clinically significant abnormalities and no LBBB, QRS duration >140ms, or evidence of prior infarction; Echocardiography with LVEF <55%; Previous documented coronary artery disease or congestive heart failure (>NYHA II)
Patients have adequate bone marrow, kidney, liver, heart, and lung function without clinically significant laboratory parameters as judged by the investigator. 12-lead ECG without clinically significant abnormalities and no LBBB, QRS duration >140ms, or evidence of prior infarction. Echocardiography with LVEF <55%. Previous documented coronary artery disease or congestive heart failure (>NYHA II).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06746688 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received anticancer therapy.
Does this trial require ERBB2?
Yes, ERBB2 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages